The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment

Molecules

Volumn 19, Issue 5, 2014, Pages 6393-6406

  D'Anzeo, Marco ^a   Faloppi, Luca ^a   Scartozzi, Mario ^a   Giampieri, Riccardo ^a   Bianconi, Maristella ^a   Del Prete, Michela ^a   Silvestris, Nicola ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

HCC; Hepatocellular carcinoma; MiRNAs

Indexed keywords

MICRORNA; TUMOR MARKER;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901426240     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19056393     Document Type: Review

References (80)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2, 533-543.
2. Gomaa A.I.; Khan S.A.; Toledano M.B.; Waked I.; Taylor-Robinson S.D. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008, 14, 4300-4308.
3. Schwartz M.; Roayaie S.; Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol. 2007, 4, 424-432.
4. Poon R.T.; Fan S.T. Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome. Liver Transpl. 2004, 10, S39-S45.
5. miRBase: The microRNA database. Available online: http://www.mirbase.org (accessed on 10 May 2014).
6. Carthew R.W.; Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 2009, 136, 642-655.
7. Friedman R.C.; Farh K.K.; Burge C.B.; Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92-105.
8. Gramantieri L.; Ferracin M.; Fornari F.; Veronese A.; Sabbioni S.; Liu C.-G.; Calin G.A.; Giovannini C.; Ferrazzi E.; Grazi G.L.; et al. Cyclin G1 is a target of miR-122a, a MicroRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67, 6092-6099.
9. Wang Y.; Lee A.T.C.; Ma J.Z.I.; Wang J.; Ren J.; Yang Y.; Tantoso E.; Li K.-B.; Jooi L.L.P.; Tan P.; et al. Profiling MicroRNA expression in hepatocellular carcinoma reveals MicroRNA-224 up-regulation and apoptosis inhibitor-5 as a MicroRNA 224-specific target. J. Biol. Chem. 2008, 283, 13205-13215.
10. Wong Q.W.-L.; Lung R.W.-M.; Law P.T.-Y.; Lai P.B.-S.; Chan K.Y.-Y.; To K.-F.; Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of stathmin. Gastroenterology 2008, 135, 257-269.
11. Budhu A.; Jia H.-L.; Forgues M.; Liu C.-G.; Goldstein D.; Lam A.; Zanetti K.A.; Ye Q.-H.; Qin L.-X.; Croce C.M.; et al. Identification of metastasis-related MicroRNAs in hepatocellular carcinoma. Hepatology 2008, 47, 897-907.
12. Fornari F.; Gramantieri L.; Ferracin M.; Veronese A.; Sabbioni S.; Calin G.A.; Grazi G.L.; Giovannini C.; Croce C.M.; Bolondi L.; et al. miR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 2, 5651-5661.
13. Bushati N.; Cohen S.M. MicroRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23, 175-205.
14. Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
15. Carleton M.; Cleary M.A.; Linsley P.S. MicroRNAs and cell cycle regulation. Cell Cycle 2007, 6, 2127-2132.
16. Boehm M.; Slack F.J. MicroRNA control of lifespan and metabolism. Cell Cycle 2006, 5, 837-840.
17. Harfe B.D. MicroRNAs in vertebrate development. Curr. Opin. Genet. Dev. 2005, 15, 410-415.
18. Han J.; Lee Y.; Yeom K.H.; Kim Y.K.; Jin H.; Kim V.N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004, 18, 3016-3027.
19. Yi R.; Qin Y.; Macara I.G.; Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17, 3011-3016.
20. Huang S.; He X. The role of microRNAs in liver cancer progression. Br. J. Cancer 2011, 104, 235-240.
21. Lujambio A.; Lowe S.W. The microcosmos of cancer. Nature 2012, 482, 347-355.
22. Otsuka M.; Kishikawa T.; Yoshikawa T.; Ohno M.; Takata A.; Shibata C.; Koike K. The role of microRNAs in hepatocarcinogenesis: Current knowledge and future prospects. J. Gastroenterol. 2014, 49, 173-184.
23. Liu W.H.; Yeh S.H.; Chen P.J. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim. Biophys. Acta 2011, 1809, 678-685.
24. Wang B.; Majumder S.; Nuovo G.; Kutay H.; Volinia S.; Patel T.; Schmittgen T.D.; Croce C.; Ghoshal K.; Jacob S.T. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by cholinedeficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009, 50, 1152-1161.
25. Liu W.H.; Yeh S.H.; Lu C.C.; Yu S.-L.; Chen H.-Y.; Lin C.-Y.; Chen D.-S.; Chen P.-J. MicroRNA-18a prevents estrogen receptor-expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009, 136, 683-693.
26. Saito Y.; Kanai Y.; Nakagawa T.; Sakamoto M.; Saito H.; Ishii H.; Hirohashi S. Increased protein expression of DNA methyl transferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer 2003, 105, 527-532.
27. Zhang X.; Zhang E.; Ma Z.; Pei R.; Jiang M.; Schlaak J.F.; Roggendorf M.; Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011, 53, 1476-1485.
28. Wang Y.; Lu Y.; Toh S.T.; Sung W.-K.; Tan P.; Chow P.; Chung A.Y.F.; Jooi L.L.P.; Lee C.G.L. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J. Hepatol. 2010, 53, 57-66.
29. Hou W.; Tian Q.; Zheng J.; Bonkovsky H.L. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010, 51, 1494-1504.
30. Yin H.; Hu M.; Zhang R.; Shen Z.; Flatow L.; You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J. Biol. Chem. 2012, 287, 9817-9826.
31. Ladeiro Y.; Couchy G.; Balabaud C.; Bioulac-Sage P.; Pelletier L.; Rebouissou S.; Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47, 1955-1963.
32. Vinciguerra M.; Sgroi A.; Veyrat-Durebex C.; Rubbia-Brandt L.; Buhler L.H.; Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009, 49, 1176-1184.
33. Hou J.; Lin L.; Zhou W.; Wang Z.; Ding G.; Dong Q.; Qin L.; Wu X.; Zheng Y.; Yang Y.; et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19, 232-243.
34. Kutay H.; Bai S.; Datta J.; Motiwala T.; Pogribny I.; Frankel W.; Jacob1 S.T.; Ghoshal K. Down regulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99, 671-678.
35. Coulouarn C.; Factor V.M.; Andersen J.B.; Durkin M.E.; Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28, 3526-3536.
36. Kojima K.; Takata A.; Vadnais C.; Otsuka M.; Yoshikawa T.; Akanuma M.; Kondo Y.; Kang Y.J.; Kishikawa T.; Kato N.; et al. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat. Commun. 2011, 2, 338.
37. He T.L.; Zheng K.L.; Li G.; Song B.; Zhang Y.J. Identification of typical miRNAs and target genes in hepatocellular carcinoma by DNA microarray technique. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 108-116.
38. Morita K.; Taketomi A.; Shirabe K.; Umeda K.; Kayashima H.; Ninomiya M.; Uchiyama H.; Soejima Y.; Maehara Y.; Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 2011, 31, 474-484.
39. Chang J.; Nicolas E.; Marks D.; Sander C.; Lerro A.; Buendia M.A.; Xu C.; Mason W.S.; Moloshok T.; Bort R.; et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004, 1, 106-113.
40. Burchard J.; Zhang C.; Liu A.M.; Poon R.T.; Lee N.P.; Wong K.F.; Sham P.C.; Lam B.Y.; Ferguson M.D.; Tokiwa G.; et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol. Syst. Biol. 2010, 6, 1-12.
41. Tsai W.C.; Hsu P.W.; Lai T.C.; Chau G.-Y.; Lin C.-W.; Chen C.-M.; Lin C.-D.; Liao Y.-L.; Wang J.-L.; Chau Y.-P.; et al. MicroRNA-122, a tumour suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49, 1571-1582.
42. Lin C.J.; Gong H.Y.; Tseng H.C.; Wang W.L.; Wu J.L. miR-122 targets an anti-Apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 375, 315-320.
43. Meng F.; Henson R.; Wehbe-Janek H.; Ghoshal K.; Jacob S.T.; Patel T. MicroRNA-21 regulates expression of the PTEN tumour suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647-658.
44. Su H.; Yang J.R.; Xu T.; Huang J.; Xu L.; Yuan Y.; Zhuang S.M. MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumourigenicity. Cancer Res. 2009, 69, 1135-1142.
45. Connolly E.; Melegari M.; Landgraf P.; Tchaikovskaya T.; Tennant B.C.; Slagle B.L.; Rogler L.E.; Zavolan M.; Tuschl T.; Rogler C.E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-Associated hepatocellular carcinoma contributes to the malignant phenotype. Am. J. Pathol. 2008, 173, 856-864.
46. Li S.; Fu H.; Wang Y.; Tie Y.; Xing R.; Zhu J.; Sun Z.; Wei L.; Zheng X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2008, 49, 1194-1202.
47. Datta J.; Kutay H.; Nasser M.W.; Nuovo G.J.; Wang B.; Majunder S.; Liu C.-G.; Volinia S.; Croce C.M.; Schmittgen T.D.; et al. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68, 5049-5058.
48. Liu C.; Yu J.; Yu S.; Lavker R.M.; Cai L.; Liu W.; Yang K.; He X.; Chen S. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J. Hepatol. 2010, 53, 98-107.
49. Galardi S.; Mercatelli N.; Giorda E.; Massalini S.; Frajese G.V.; Ciafre S.A.; Farace M.G. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 2007, 282, 23716-23724.
50. Zhang Y.; Wei W.; Cheng N.; Wang K.; Li B.; Jiang X.; Sun S. Hepatitis C Virus-induced up-regulation of miR-155 promotes hepatocarcinogenesis by activating Wntsignaling. Hepatology 2012, 56, 1631-1640.
51. Yao J.; Liang L.; Huang S.; Ding J.; Tan N.; Zhao Y.; Yan M.; Ge C.; Zhang Z.; Chen T.; et al. MicroRNA-30d promotes tumour invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology 2010, 51, 846-856.
52. Ding J.; Huang S.; Wu S.; Zhao Y.; Liang L.; Yan M.; Ge C.; Yao J.; Chen T.; Wan D.; et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol. 2010, 12, 390-399.
53. Yang J.; Zhou F.; Xu T.; Deng H.; Ge Y.Y.; Zhang C.; Li J.; Zhuang S.-M. Analysis of sequence variations in 59 microRNAs in hepatocellular carcinomas. Mutat. Res. 2008, 638, 205-209.
54. Akkiz H.; Bayram S.; Bekar A.; Akgollu E.; Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: A case-control study. J. Viral Hepat. 2011, 18, e399-e407.
55. Qi P.; Dou T.H.; Geng L.; Zhou F.G.; Gu X.; Wang H.; Gao C.F. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum. Immunol. 2010, 71, 621-626.
56. Sekine S.; Ogawa R.; Ito R.; Hiraoka N.; McManus M.T.; Kanai Y.; Hebrok M. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009, 136, 2304-2315.
57. Iorio M.V.; Piovan C.; Croce C.M. Interplay between microRNAs and the epigenetic machinery: An intricate network. Biochim. Biophys. Acta 2010, 1799, 694-701.
58. Lim L.; Balakrishnan; A.; Huskey N.; Jones K.D.; Jodari M.; Ng R.; Song G.; Riordan J.; Anderton, B; Cheung S.-T.; et al. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2014, 59, 202-215.
59. Li L.; Tang J.; Zhang B.; Yang W.; Liugao M.; Wang R.; Tan Y.; Fan J.; Chang Y.; Fu J.; et al. Epigenetic modification of MiR-429 promotes liver tumour-initiating cell properties by targeting Rb binding protein 4. Gut 2014, doi:10.1136/gutjnl-2013-305715.
60. Xu L.; Beckebaum S.; Iacob S.; Wu G.; Kaiser G.M.; Radtke A.; Liu C.; Kabar I.; Schmidt H.H.; Zhang X.; et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J. Hepatol. 2014, 60, 590-598.
61. Oka H.; Tamori A.; Kuroki T.; Kobayashi K.; Yamamoto S. Prospective study of alphafetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19, 61-66.
62. Abdalla M.A.; Haj-Ahmad Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J. Cancer 2012, 3, 19-31.
63. Chen X.; Ba Y.; Ma L.; Cai X.; Yin Y.; Wang K.; Guo J.; Zhang Y.; Chen J.; Guo X.; et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997-1006.
64. Mitchell P.S.; Parkin R.K.; Kroh E.M.; Fritz B.R.; Wyman S.K.; Pogosova-Agadjanyan E.L.; Peterson A.; Noteboom J.; O'Briant K.C.; Allen A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
65. Li L.M.; Hu Z.B.; Zhou Z.X.; Chen X.; Liu F.Y.; Zhang J.F.; Shen H.-B.; Zhang C.-Y.; Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70, 9798-9807.
66. Zhou J.; Yu L.; Gao X.; Hu J.; Wang J.; Dai Z.; Wang J.-F.; Zhang Z.; Lu S.; Huang X.; et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 2011, 29, 4781-4788.
67. Yamashita T.; Forgues M.; Wang W.; Kim J.W.; Ye Q.; Jia H.; Budhu A.; Zanetti K.A.; Chen Y.; Qin L.-X.; et al. EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008, 68, 1451-1461.
68. Yamashita T.; Ji J.; Budhu A.; Forgues M.; Yang W.; Wang H.-Y.; Jia H.; Ye Q.; Qin L.-X.; Wauthier E.; et al. EpCAM-Positive hepatocellular carcinoma cells are tumour-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136, 1012-1024.
69. Ji J.; Yamashita T.; Budhu A.; Forgues M.; Jia H.-L.; Li C.; Deng C.; Wauthier E.; Reid L.M.; Ye Q.-H.; et al. Identification of MicroRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50, 472-480.
70. Wong C.M.; Wong C.C.; Lee J.M.; Fan D.N.; Au S.L.; Ng I.O. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012, 55, 1453-1461.
71. Ji J.; Shi J.; Budhu A.; Yu Z.; Forgues M.; Yu Z.; Forgues M.; Roessler S.; Ambs S.; Chen Y.; et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009, 361, 1437-1447.
72. Wei R.; Huang G.-L.; Zhang M.Y.; Li B.-K.; Zhang H.-Z.; Shi M.; Chen X.-Q.; Huang L.; Zhou Q.-M.; Jia W.-H.; et al. Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin. Cancer Res. 2013, 19, 4780-4791.
73. Krützfeldt J.; Kuwajima S.; Braich R.; Rajeev K.G.; Pena J.; Tuschl T.; Manoharan M.; Stoffel M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucl. Acids Res. 2007, 35, 2885-2892.
74. Bader A.G.; Brown D.; Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027-7030.
75. Kota J.; Chivukula R.R.; O'Donnell K.A.; Wentzel E.A.; Montgomery C.L.; Hwang H.-W.; Chang T.-C.; Vivekanandan P.; Torbenson M.; Clark K.R.; et al. Therapeutic microRNA delivery suppresses tumourigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
76. Bai S.; Nasser M.W.; Wang B.; Hsu S.H.; Datta J.; Kutay H.; Yadav A.; Nuovo G.; Kumar P.; Ghoshal K. MicroRNA-122 inhibits tumourigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 2009, 284, 32015-32027.
77. Xu Y.; Xia F.; Ma L.; Shan J.; Shen J.; Yang Z.; Liu J.; Cui Y.; Bian X.; Bie P.; et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 2011, 310, 160-169.
78. Yang F.; Zhang L.; Wang F.; Wang Y.; Huo X.S.; Yin Y.X.; Wang Y.Q.; Zhang L.; Sun S.H. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia 2011, 13, 590-600.
79. Ling H.; Fabbri M.; Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12, 847-865.
80. Shibata C.; Otsuka M.; Kishikawa T.; Yoshikawa T.; Ohno M.; Takata A.; Koike K.A. Current status of miRNA-Targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol. Cell. Ther. 2013, 1, 5.